Rigel’s Fostamatinib and Kissei Pharmaceuticals progress with a Phase III trial of their medicine for Chronic Immune Thrombocytopenia patients

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. (“Kissei”), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune thrombocytopenia (ITP). By comparing it with…